AstraZeneca PLC (AZN): One of the Best Low Risk High Growth Firms [Yahoo! Finance]
AstraZeneca PLC Ordinary Shares (AZN)
Last astrazeneca plc ordinary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
The growth story for AstraZeneca PLC (NYSE:AZN) is built on a massive, contractually visible expansion plan. Earlier this year, CEO Pascal Soriot reaffirmed the company's goal to reach $80 billion in annual revenue by 2030. For a company currently reporting roughly $59 billion, this represents an industry-leading growth trajectory. In Q1 2026, cancer drug sales jumped 20%, fueled by blockbuster performance from Tagrisso, Imfinzi, and the accelerating Enhertu portfolio. These high-margin antibody-drug conjugates are viewed by hedge funds as the primary growth engine for the next decade. Safety in pharma comes from having so many products that a single failure cannot sink the stock. AstraZeneca owns 16 different blockbuster medicines, drugs generating over $1 billion annually. Piper Sandler Maintains Overweight Rating on Blue Owl Capital (OWL) In 2026 alone, AstraZeneca PLC (NYSE:AZN) is expecting results from more than 20 Phase III clinical trials. This strategy significantly de-r
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC Ordinary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and olderBusiness Wire
- SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosusBusiness Wire
- AstraZeneca PLC (AZN) Announces Positive Results From a Prespecified Interim Analysis of the I CAN Phase III Trial [Yahoo! Finance]Yahoo! Finance
- AstraZeneca Achieves Positive Phase III Results for COPD Drug [TheStreet.com]TheStreet.com
- Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPDBusiness Wire
AZN
Sec Filings
- 4/28/26 - Form SCHEDULE
- 4/28/26 - Form 6-K
- 4/27/26 - Form 6-K
- AZN's page on the SEC website